Immunocore to present at upcoming investor conferences
Immunicore Holdings plc will be participating in several investor conferences in April. The management will be presenting at the Needham Virtual Healthcare Conference, Canaccord Horizons in Oncology, and the Kempen Life Sciences Conference to discuss the company’s innovative immunomodulating medicines. The presentations will cover a range of topics, including T-cell engagers for solid tumors and the development of ImmTAX therapies for various diseases. For those unable to attend the events, webcasts will be available on the company’s website, with replays accessible for a limited time after the conferences.
Immunocore is a leading biotechnology company focused on developing TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune diseases. With a strong pipeline of clinical and pre-clinical programs, the company is at the forefront of revolutionizing treatment options for patients. The recent approval of KIMMTRAK (tebentafusp) for uveal melanoma underscores Immunocore’s commitment to delivering transformative therapies. Investors and stakeholders are encouraged to attend the upcoming conferences to learn more about the company’s groundbreaking work in the field of immunotherapy.
